SUPPLEMENTAL DATA
Supplemental Table 1. Body composition before and after recombinant human erythropoietin (rHuEPO) treatment. Mean ± SD values for body weight, body mass index (BMI), fat mass (FM), fat free mass (FFM) and body fat percentage (BF%) *, P<0.05 difference between the two treatment groups. #, P<0.05 difference between males and females.
Supplementary table 1. Body composition
Body weight (kg) BMI FM
(kg) FFM (kg) BF%
rHuEPO
Average (n=24)
PRE mean 72.1 23.4 6.0 58.4 18.0
SD 10.0 1.9 2.0 10.2 5.5
POST mean 72.1 23.4 6.1 58.5 18.6
SD 10.1 1.9 2.1 9.7 5.8
Male (n=12)
PRE mean 77.5# 23.5 5.7# 66.3# 15.6#
SD 7.8 23.5 2.5 5.5 6.0
POST mean 77.6# 2.3 5.7# 65.7# 15.9#
SD 7.9 1.4 2.6 5.7 6.5
Female (n=12)
PRE mean 66.5 23.3 6.3 50.6 20.5
SD 9.0 1.4 1.5 7.2 3.8
POST mean 66.5 23.3 6.3 51.1 21.2
SD 9.0 1.4 1.6 6.9 3.6
Placebo
Average (n=24)
PRE mean 69.4 21.9 5.5 56.7 17.9
SD 11.2 2.3 1.7 11.4 5.7
POST mean 69.9 21.8 5.5 56.3 18.0
SD 11.1 2.3 1.8 11.8 5.8
Male (n=12)
PRE mean 76.3# 22.7 5.1# 65.4# 14.9#
SD 8.8 2.1 1.8 8.5 5.7
POST mean 76.0# 22.6 5.1# 65.8# 14.9#
SD 9.2 2.2 1.7 9.0 5.4
Female (n=12)
PRE mean 62.5* 2.1 5.9 47.9 20.8
SD 8.8 2.2 1.7 5.4 4.0
POST mean 62.5* 2.1 5.9 47.6 20.8
SD 8.3 2.1 1.9 5.5 4.9
Supplemental Table 2. Mean ± SD values for systolic (Sys) and disastolic (Dia) blood pressure during and 3, 5, and 10 days after recombinant human erythropoietin (rHuEPO) or placebo treatment. No statistical differences were found.
Supplementary table 2. Blood pressure.
Week 1 Week 2 Week 3 Week 4 3 Days 5 Days 10 Days
Sys (mmHg
)
Dia (mmHg
)
Sys (mmHg
)
Dia (mmHg
)
Sys (mmHg
)
Dia (mmHg
)
Sys (mmHg
)
Dia (mmHg
)
Sys (mmHg
)
Dia (mmHg
)
Sys (mmHg
)
Dia (mmHg
)
Sys (mmHg
)
Dia (mmHg
)
rHuEPO
Averag e (n=24)
mea
n 117 75 117 75 116 75 115 76 118 75 116 74 116 76
SD 10 8 8 10 13 9 10 9 11 7 12 6 11 9
Male (n=12)
mea
n 122 76 120 73 120 76 120 76 125 76 123 75 121 77
SD 7 7 8 9 10 9 7 6 10 6 11 8 10 10
Female (n=12)
mea
n 113 75 114 76 113 74 110 77 112 74 110 73 110 75
SD 11 9 8 10 14 9 11 12 8 9 7 5 9 8
Placebo
Averag e (n=24)
mea
n 113 73 116 73 113 75 114 72 114 74 114 74 115 74
SD 11 9 10 8 9 6 12 9 11 9 12 7 13 9
Male (n=12)
mea
n 119 76 122 75 118 77 123 75 121 75 121 75 128 81
SD 12 11 8 10 8 6 7 9 11 13 8 8 7 8
Female (n=12)
mea
n 107 71 109 71 109 73 105 70 107 74 102 73 105 69
SD 8 5 6 3 8 6 9 10 6 5 5 4 5 6
Supplemental Table 3. Mean ± SD values for pulmonary data, heart rate (HR) and mean power output (MPO) before (PRE) and after (POST) treatment with recombinant human erythropoietin (rHuEPO) or placebo. V̇E: ventilation, V̇O
2: oxygen uptake, V̇CO
2: carbondioxide exhalation, RER:
respiratory exchange ratio.
Supplementary table 3. One-hour preload – power and physiological data.
MP O (W)
HR (BPM
)
VE (L×min-1)
V̇O2
(ml×min-1)
V̇CO2
(ml×min-1)
RE R
rHuEPO
Average (n=24)
PRE mea
n 168 136 57 2311 2071 0.90
SD 39 11 13 534 489 0.04
POS T
mea
n 169 133 59 2313 2151 0.93
SD 40 11 14 541 486 0.05
Male (n=12)
PRE mea
n 195 129 66 2741 2473 0.90
SD 35 10 12 427 384 0.03
POS T
mea
n 196 128 67 2709 2512 0.93
SD 35 9 13 425 380 0.03
Female (n=12) PRE
mea
n 141 142 48 1917 1702 0.89
SD 20 9 7 226 183 0.04
POS T
mea
n 141 139 49 1877 1754 0.94
SD 20 10 7 218 175 0.07
Placebo
Average (n=24)
PRE mea
n 166 136 58 2322 2088 0.89
SD 32 12 14 588 495 0.02
POS T
mea
n 166 136 60 2372 2164 0.91
SD 33 12 11 456 405 0.04
Male (n=12)
PRE mea
n 190 139 67 2709 2418 0.90
SD 19 15 12 475 385 0.02
POS T
mea
n 191 133 66 2684 2451 0.91
SD 18 12 9 315 290 0.03
Female (n=12) PRE
mea
n 141 134 50 1934 1757 0.91
SD 24 8 11 412 355 0.03
Supplemental Table 4. Mean ± SD values for blood metabolites and ions before and after treatment with recombinant human erythropoietin (rHuEPO) or placebo. For clarity, any ‘time’
main effects are not denoted.
Supplementary table 4. Blood metabolites and ions during preload and time trial BEFORE TREATMENT
PRELOAD pH Lactate
(mmol/L) Glucose
(mmol/L) Na+
(mmol/L) K+
(mmol/L) HCO3-
(mmol/L)
pre rHuEPO
PLA
7.410 ± 0.022 7.407 ± 0.019
1.6 ± 0.4 1.7 ± 0.5
5.9 ± 0.9 6.1 ± 1.0
141 ± 2 141 ± 5
4.6 ± 0.3 4.5 ± 0.4
23.9 ± 1.8 24.0 ± 1.5
30 min rHuEPO
PLA
7.408 ± 0.025 7.413 ± 0.020
2.2 ± 0.7 2.8 ± 1.2
5.6 ± 0.8 5.6 ± 0.7
141 ± 2 143 ± 2
5.5 ± 0.5 5.9 ± 1.0
23.1 ± 2.8 23.3 ± 1.7
60 min rHuEPO
PLA
7.409 ± 0.020 7.412 ± 0.019
2.0 ± 0.7 2.3 ± 1.1
5.8 ± 0.7 5.9 ± 0.8
141 ± 2 142 ± 2
5.3 ± 0.4 5.2 ± 0.6
23.6 ± 1.7 22.8 ± 2.5
TIME TRIAL pH Lactate
(mmol/L)
Glucose (mmol/L)
Na+ (mmol/L)
K+ (mmol/L)
HCO3-
(mmol/L)
0 kcal rHuEPO
PLA
7.412 ± 0.025 7.408 ± 0.016
1.7 ± 0.8 2.1 ± 1.1
6.1 ± 0.8 6.1 ± 0.8
141 ± 1 142 ± 2
4.8 ± 0.4 4.9 ± 0.5
24.0 ± 2.7 23.6 ± 1.5 200 kcal rHuEPO
PLA
7.370 ± 0.057 7.369 ± 0.040
6.9 ± 3.2 8.3 ± 4.1
4.7 ± 0.7 4.7 ± 0.9
143 ± 3 144 ± 3
6.1 ± 0.6 6.1 ± 0.6
18.4 ± 3.3 18.2 ± 3.0 400 kcal rHuEPO
PLA
7.291 ± 0.061 7.297 ± 0.048
11.3 ± 4.1 12.9 ± 5.1
5.7 ± 1.2 5.8 ± 1.4
144 ± 3 145 ± 3
6.4 ± 0.7 6.4 ± 0.8
14.5 ± 3.1 14.4 ± 2.7 AFTER TREATMENT
PRELOAD pH Lactate
(mmol/L) Glucose
(mmol/L) Na+
(mmol/L) K+
(mmol/L) HCO3-
(mmol/L)
pre rHuEPO
PLA
7.410 ± 0.018 7.406 ± 0.017
1.6 ± 0.6 1.9 ± 0.7
6.2 ± 1.3 6.0 ± 1.1
140 ± 5 140 ± 5
4.5 ± 0.3 4.7 ± 0.8
24.0 ± 2.0 24.0 ± 1.3
30 min rHuEPO
PLA
7.408 ± 0.022 7.409 ± 0.016
2.2 ± 0.9 2.1 ± 0.7
5.9 ± 1.0 5.7 ± 0.8
142 ± 3 142 ± 3
5.5 ± 0.7 5.5 ± 0.6
23.6 ± 1.8 23.6 ± 1.4
60 min rHuEPO
PLA
7.414 ± 0.020 7.412 ± 0.020
2.0 ± 0.9 2.1 ± 0.8
6.1 ± 0.8 6.0 ± 0.8
141 ± 3 141 ± 3
5.3 ± 0.7 5.3 ± 0.6
23.5 ± 1.8 23.1 ± 1.6
TIME TRIAL pH Lactate
(mmol/L)
Glucose (mmol/L)
Na+ (mmol/L)
K+ (mmol/L)
HCO3-
(mmol/L)
0 kcal rHuEPO
PLA
7.414 ± 0.021 7.402 ± 0.023
1.7 ± 0.5 1.8 ± 0.5
6.2 ± 1.0 6.3 ± 1.2
141 ± 3 141 ± 3
4.8 ± 0.4 4.8 ± 0.7
23.8 ± 2.1 23.7 ± 1.7 200 kcal rHuEPO
PLA
7.356 ± 0.055 7.364 ± 0.057
8.5 ± 4.7 7.9 ± 3.1
5.2 ± 1.1 4.8 ± 1.2
143 ± 3 143 ± 3
6.1 ± 1.0 6.1 ± 0.8
17.7 ± 3.3 18.0 ± 3.6 400 kcal rHuEPO
PLA
7.302 ± 0.058 7.290 ± 0.056
11.8 ± 5.1 11.7 ± 3.1
6.1 ± 1.5 6.0 ± 1.4
144 ± 3 144 ± 3
6.2 ± 0.6 6.0 ± 0.6
14.5 ± 2.9 14.5 ± 3.1
